(Q37963173)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22130117%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

title

Development and clinical utility of abiraterone acetate as an androgen synthesis inhibitor (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22130117%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference

ChEBI release 2020-05-28

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22130117%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

author name string

C J Ryan

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22130117%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

language of work or name

English

0 references

publication date

30 November 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22130117%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacology & Therapeutics

17 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22130117%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

volume

91

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22130117%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22130117%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

page(s)

101-108

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22130117%20AND%20SRC:MED&resulttype=core&format=json

New developments in the medical management of prostate cancer

17 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.275

Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.275

Castration-recurrent prostate cancer is not androgen-independent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.275

Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.275

Contribution of the androgen receptor to prostate cancer predisposition and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.275

Progression of prostate cancer by synergy of AKT with genotropic and nongenotropic actions of the androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.275

The development of androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.275

Androgen receptor abnormalities in castration-recurrent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.275

Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.275

The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.275

Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.275

Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17). Part I: Heterocyclic modifications of the core structure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.275

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.275

Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.275

Flushing oral oncology drugs down the toilet

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.275

Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.275

Pregnenolone stimulates LNCaP prostate cancer cell growth via the mutated androgen receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.275

Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.275

Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.275

Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.275

Abiraterone and increased survival in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.275

Abiraterone acetate is well tolerated without concomitant use of corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.275

Effects of novel 17alpha-hydroxylase/C17, 20-lyase (P450 17, CYP 17) inhibitors on androgen biosynthesis in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.275

Expanding treatment options for metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.275

Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.275

Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.275

Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.275

Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.275

Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.275

Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.275

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.275

PI3K/Akt and apoptosis: size matters

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.275

Is PTEN loss associated with clinical outcome measures in human prostate cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.275

PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.275

Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.275

Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.275

Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.275

Genomic strategy for targeting therapy in castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.275

Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.275

Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.275

Circulating tumor cells as biomarkers in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.275

The 16,17-double bond is needed for irreversible inhibition of human cytochrome p45017alpha by abiraterone (17-(3-pyridyl)androsta-5, 16-dien-3beta-ol) and related steroidal inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.275

7 January 2021

3- and 4-pyridylalkyl adamantanecarboxylates: inhibitors of human cytochrome P450(17 alpha) (17 alpha-hydroxylase/C17,20-lyase). Potential nonsteroidal agents for the treatment of prostatic cancer

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.275

7 January 2021

Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.275

7 January 2021

10q23.3 loss of heterozygosity is higher in lymph node-positive (pT2-3,N+) versus lymph node-negative (pT2-3,N0) prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.275

7 January 2021